The Core Role of β-NGF in Osteoarthritis Pain and Its Research Progress as a Therapeutic Target

Based on the challenges in the clinical treatment of osteoarthritis (OA), this article systematically elaborates on the key role of nerve growth factor β (β-NGF) in the occurrence and transmission of OA pain and its research progress as a novel therapeutic target, while analyzing the efficacy and safety challenges of NGF-targeted therapy.

Recent Advances
Product Information

Recent Advances

The Pivotal Role of β-NGF in Osteoarthritis Pain and Advances in Its Therapeutic Targeting

Summary
This article systematically elucidates the critical role of β-nerve growth factor (β-NGF) in the initiation and transmission of osteoarthritis (OA) pain and its potential as a novel therapeutic target, based on the challenges in clinical OA management. It also analyzes the efficacy and safety concerns of NGF-targeted therapies.

I. Therapeutic Challenges and Unmet Needs in Osteoarthritis.

Osteoarthritis is the most common degenerative joint disease and a leading cause of disability in the elderly. With the aging population in China, the number of OA patients is increasing annually. However, OA receives far less clinical attention compared to other arthritic diseases, and effective treatments remain lacking. Current first-line medications, such as nonsteroidal anti-inflammatory drugs and corticosteroids, provide only short-term relief without altering disease progression. More critically, unlike disease-modifying antirheumatic drugs for rheumatoid arthritis, no disease-modifying OA drugs (DMOADs) that can genuinely alleviate both OA progression and pain have been approved, rendering OA an incurable condition. The clinical heterogeneity of OA, involving different phenotypes and affected structures as the disease progresses, makes it difficult to develop a universal therapy. Thus, personalized treatment plans tailored to patient phenotypes and disease severity have become a key focus.

II. Exploration and Discovery of Novel Therapeutic Targets.

With deeper insights into OA pathogenesis, target molecules closely associated with OA development, such as BMP-7, ADAMTS-5, and β-NGF, have been identified. Among these, β-nerve growth factor (β-NGF) stands out as one of the most promising targets due to its central role in OA pain transmission. NGF is a soluble neuropeptide belonging to the neurotrophin family, involved in nervous system development and pain processing. In OA, NGF levels are significantly elevated in synovial tissues, playing a key role in peripheral sensitization. Studies confirm that activation of the NGF/TrkA signaling pathway promotes the release of pain mediators, increases sensory nerve fiber innervation in synovial tissues, and exacerbates peripheral hyperalgesia. β-NGF expression positively correlates with visual analog scale (VAS) pain scores in OA patients (r=0.34), and the ratio of NGF to soluble TrkA receptors shows an even stronger correlation with pain scores (r=0.80).

III. Advances and Challenges in NGF-Targeted Therapy.

Direct NGF antagonism has been shown to alleviate OA pain, but some studies associate it with rapidly progressive OA, raising safety concerns. Currently, monoclonal antibodies targeting NGF demonstrate promising analgesic effects in clinical trials, though their long-term safety requires further validation. In rat OA models, the selective COX-2 inhibitor etoricoxib reduces cartilage degeneration and lowers NGF expression. In KOA rat models, intra-articular injection of NGF protein exacerbates peripheral hyperalgesia, while siRNA-mediated TrkA interference partially reverses these effects. These findings highlight the NGF/TrkA signaling axis as a crucial target for OA pain management, but therapeutic strategies must be carefully designed to balance efficacy and safety.

IV. Research Applications of Rat-Derived β-NGF Recombinant Protein.

High-quality rat-derived β-NGF recombinant protein serves as a vital tool molecule in OA pain mechanism studies and NGF-targeted drug screening. Its applications include: serving as a standard for quantifying β-NGF levels in serum or joint fluid of rat models; studying NGF/TrkA signaling pathway activation mechanisms in cultured dorsal root ganglion cells or synovial fibroblasts; evaluating the blocking activity of candidate antibodies or small-molecule inhibitors on NGF-receptor binding; and acting as an immunogen for preparing specific antibodies for immunohistochemistry or Western Blot assays. To meet these research needs, Uni offers β-NGF Protein, Rat, suitable for OA pain mechanism studies, in vitro activity assessment of NGF-targeted drugs, and establishment of related immunoassay methods.

V. Conclusion.

As a key mediator of OA pain transmission, β-NGF has emerged as an important target for novel therapeutic development. Although NGF-targeting antibody drugs demonstrate promising analgesic effects in clinical trials, safety concerns remain a major challenge for clinical translation. Rat-derived β-NGF recombinant protein, as a core tool for basic research and drug screening, will continue to play a pivotal role in advancing OA pain mechanism elucidation and the development of new analgesic therapies.

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next